Lung cancer Posts on Medivizor

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Posted by Medivizor on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of toripalimab (Tuoyi) in combination with chemotherapy as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that toripalimab in combination with chemotherapy significantly improved overall survival and survival without cancer...

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by Medivizor on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by Medivizor on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by Medivizor on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Comparing the effectiveness and safety between immune checkpoint inhibitors and docetaxel in patients with non-small cell lung cancer.

Posted by Medivizor on Feb 27, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety between immune checkpoint inhibitors (ICIs) and docetaxel (Taxotere) therapy alone in patients with non-small cell lung cancer (NSCLC). The data showed ICIs significantly improved the survival outcomes with fewer serious side effects compared to docetaxel alone for the treatment of patients...

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Posted by Medivizor on Jan 3, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the...

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by Medivizor on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by Medivizor on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Posted by Medivizor on Dec 4, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo)...

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Posted by Medivizor on Nov 22, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with tiragolumab (MTIG7192A) as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The data showed that tiragolumab plus atezolizumab significantly improved the objective response rate and the survival without...

Evaluating the effectiveness and safety of adebrelimab plus standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Posted by Medivizor on Oct 16, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of adebrelimab (SHR-1316) plus carboplatin (Paraplatin) and etoposide (Etopophos)-based chemotherapy as first-line treatment for extensive-stage (ES) small-cell lung cancer (SCLC). The data showed that adebrelimab added to standard chemotherapy as first-line treatment...

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by Medivizor on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Lung cancer Posts on Medivizor

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Comparing the effectiveness and safety between immune checkpoint inhibitors and docetaxel in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of adebrelimab plus standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Categories

Recent Posts

Archives

Lung cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email